Alpha 1 antitrypsin is being tested in a Phase 2/3 Clinical Study to evaluate the safety and efficacy of Glassia (1-4) as an add-on bio pharmacotherapy to conventional steroid treatment in subjects with acute graft versus host disease with lower gastrointestinal involvement (NCT02956122).